Steven R Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11296982/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	4.9	56
2	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)â€Free Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	3.7	8
3	Quantifying the contribution of lipoprotein(a) to all apoB containing particles. Journal of Clinical Lipidology, 2022, 16, 220-226.	1.5	3
4	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	10.9	14
5	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper from <i>the International Lipid Expert Panel</i> (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	35
6	The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. American Journal of Cardiology, 2022, 171, 1-6.	1.6	11
7	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
8	Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm. Journal of Clinical Lipidology, 2021, 15, 104-115.e9.	1.5	6
9	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
10	Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines. American Journal of Preventive Cardiology, 2021, 7, 100203.	3.0	2
11	Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels. JAMA Network Open, 2021, 4, e2128817.	5.9	40
12	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	1.8	41
13	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 1091-1100.	1.8	61
14	The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives. Hellenic Journal of Cardiology, 2020, 61, 398-403.	1.0	15
15	Evolocumab, a PCSK9â€Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia. Journal of the American Heart Association, 2020, 9, e016263.	3.7	44
16	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	3.0	142
17	Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period. Circulation, 2020, 142, 419-421.	1.6	42
18	Evaluation and Management of PatientsÂWith Stable Angina: Beyond the Ischemia Paradigm. Journal of the American College of Cardiology, 2020, 76, 2252-2266.	2.8	52

#	Article	IF	CITATIONS
19	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.9	11
20	Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Archives of Medical Science, 2020, 16, 993-1003.	0.9	20
21	Accuracy of New Equation to Calculate Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2020, 6, 121-122.	6.1	4
22	Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Prel²-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 3062-3064.	2.8	5
23	Takotsubo Syndrome in the Setting of COVID-19. JACC: Case Reports, 2020, 2, 1321-1325.	0.6	122
24	Effect of Evolocumab on Nonâ€Highâ€Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. Journal of the American Heart Association, 2020, 9, e014129.	3.7	25
25	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
26	High‣ensitivity Câ€Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association, 2020, 9, e013600.	3.7	43
27	Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 331-338.	1.5	4
28	In reply: Infective endocarditis: Don't forget the ICE. Cleveland Clinic Journal of Medicine, 2020, 87, 192-192.	1.3	0
29	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	3.8	34
30	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal of Clinical Lipidology, 2019, 13, 634-644.	1.5	32
31	Novel Presentation of Homozygous Familial Hypercholesterolemia WithÂHomozygous Variants in BothÂLDLRÂand APOB Genes. JACC: Case Reports, 2019, 1, 346-349.	0.6	0
32	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. Archives of Medical Research, 2019, 50, 362-367.	3.3	14
33	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. Journal of Clinical Lipidology, 2019, 13, 804-811.e2.	1.5	10
34	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). Maturitas, 2019, 130, 32-37.	2.4	12
35	Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7. Archives of Medical Science, 2019, 15, 1195-1202.	0.9	16
36	Infective endocarditis: Beyond the usual tests. Cleveland Clinic Journal of Medicine, 2019, 86, 559-567.	1.3	20

#	Article	IF	CITATIONS
37	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. Current Atherosclerosis Reports, 2018, 20, 14.	4.8	11
38	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation, 2018, 138, 244-254.	1.6	34
39	Statin Safety: What Every Health Care Provider Needs to Know. Current Cardiovascular Risk Reports, 2018, 12, 1.	2.0	1
40	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHÂtrial. Journal of Clinical Lipidology, 2018, 12, 741-747.e11.	1.5	6
41	Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. Circulation, 2018, 137, 10-19.	1.6	92
42	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	1.6	29
43	Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. Current Cardiovascular Risk Reports, 2018, 12, 1.	2.0	2
44	Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Lowâ€Đensity Lipoprotein Cholesterol. Journal of the American Heart Association, 2018, 7, e009996.	3.7	40
45	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. European Heart Journal, 2018, 39, 3641-3653.	2.2	69
46	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetes and Vascular Disease Research, 2018, 15, 541-547.	2.0	6
47	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. Journal of Clinical Lipidology, 2018, 12, 1290-1297.e1.	1.5	10
48	Novel Therapeutic Targets for Managing Dyslipidemia. Trends in Pharmacological Sciences, 2018, 39, 733-747.	8.7	31
49	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. Angiology, 2017, 68, 99-108.	1.8	35
50	Serum vitamin D and change in lipid levels over 5Ây: The Atherosclerosis Risk in Communities study. Nutrition, 2017, 38, 85-93.	2.4	26
51	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. Aids, 2017, 31, 965-971.	2.2	4
52	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. Drugs, 2017, 77, 1187-1197.	10.9	29
53	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2017, 31, 419-431.	2.6	45
54	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. Journal of the American Heart Association, 2017, 6, .	3.7	39

#	Article	IF	CITATIONS
55	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Medicine, 2017, 15, 83.	5.5	38
56	Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. Archives of Medical Science, 2017, 4, 732-737.	0.9	48
57	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70Âmg/dL compared with a novel low-density lipoprotein estimation method. Journal of Clinical Lipidology, 2017, 11, 1065-1072.	1.5	37
58	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World Journal of Cardiology, 2016, 8, 201.	1,5	47
59	Triglycerides to high-density lipoprotein–cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 150-156.	2.3	71
60	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	1.6	21
61	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2016, 6, 19188.	3.3	55
62	Serum homocysteine is not independently associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-21) study. Atherosclerosis, 2016, 249, 59-64.	0.8	10
63	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2016, 107, 360-371.	7.1	61
64	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology, 2016, 12, 139-148.	1.2	5
65	Entropy of cardiac repolarization predicts ventricular arrhythmias and mortality in patients receiving an implantable cardioverter-defibrillator for primary prevention of sudden death. Europace, 2016, 18, euv399.	1.7	14
66	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	3.7	121
67	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.	0.8	142
68	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease, 2016, 15, 28.	3.0	36
69	PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients. European Heart Journal Cardiovascular Imaging, 2016, 18, jew116.	1.2	18
70	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clinical Therapeutics, 2016, 38, 603-609.	2.5	12
71	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Future Cardiology, 2016, 12, 149-157.	1.2	7
72	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological Research, 2016, 103, 236-252.	7.1	60

Steven R Jones

#	Article	IF	CITATIONS
73	Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study. Journal of Clinical Lipidology, 2016, 10, 72-81.e1.	1.5	71
74	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. European Journal of Preventive Cardiology, 2016, 23, 41-49.	1.8	64
75	Newer Lipid Markers: Apolipoprotein B, LDL Particle Concentration, and Triglyceride-Rich Lipoproteins – When Are They Needed?. , 2016, , 145-158.		0
76	mActive: A Randomized Clinical Trial of an Automated mHealth Intervention for Physical Activity Promotion. Journal of the American Heart Association, 2015, 4, .	3.7	220
77	Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clinical Cardiology, 2015, 38, 660-667.	1.8	21
78	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.9	311
79	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241, 433-442.	0.8	139
80	ldiopathic â€~true' left ventricular aneurysm. Journal of Cardiology Cases, 2015, 12, 202-204.	0.5	4
81	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	1.5	5
82	Effects of Coenzyme Q10 on Statin-Induced Myopathy. Mayo Clinic Proceedings, 2015, 90, 24-34.	3.0	168
83	Maximal Exercise Testing Variables and 10-Year Survival: Fitness Risk Score Derivation From the FIT Project. Mayo Clinic Proceedings, 2015, 90, 346-355.	3.0	31
84	Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research, 2015, 99, 329-336.	7.1	145
85	Distribution and burden of newly detected coronary artery calcium: Results from the Multi-Ethnic Study of Atherosclerosis. Journal of Cardiovascular Computed Tomography, 2015, 9, 337-344.e1.	1.3	28
86	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
87	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis, 2015, 242, 87-96.	0.8	47
88	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis, 2015, 242, 243-250.	0.8	93
89	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	2.4	117

90 Elevated Triglycerides, Atherosclerosis and Adverse Clinical Events. , 2015, , 55-67.

0

Steven R Jones

#	Article	IF	CITATIONS
91	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). Journal of Clinical Lipidology, 2015, 9, 676-683.	1.5	14
92	Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	1.7	154
93	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	2.2	142
94	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midâ€Life: The Very Large Database of Lipids (VLDLâ€10B). Journal of the American Heart Association, 2014, 3, e000851.	3.7	54
95	Letter by Jones et al Regarding Article, "Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation― Circulation, 2014, 129, e655.	1.6	13
96	Risk and the Physics of Clinical Prediction. American Journal of Cardiology, 2014, 113, 1429-1435.	1.6	37
97	2013 ACC/AHA Cholesterol Treatment Guideline. Journal of the American College of Cardiology, 2014, 63, 2674-2678.	2.8	52
98	Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease. Circulation, 2014, 129, 77-86.	1.6	212
99	Discordance in Lipid Measurements: Can we Capitalize to Better Personalize Cardiovascular Risk Assessment and Treatment?. Current Cardiovascular Risk Reports, 2014, 8, 1.	2.0	1
100	High-density lipoprotein subfractions: current views and clinical practice applications. Trends in Endocrinology and Metabolism, 2014, 25, 329-336.	7.1	42
101	Usefulness of Coronary and Carotid Imaging Rather than Traditional Atherosclerotic Risk Factors to Identify Firefighters at Increased Risk for Cardiovascular Disease. American Journal of Cardiology, 2014, 113, 1499-1504.	1.6	20
102	Effect of Equivalent On-Treatment Apolipoprotein Levels on Outcomes (from the AIM-HIGH and) Tj ETQq0 0 0 rg	;BT/Qverlc 1.0	ock 10 Tf 50 3
103	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	7.4	568
104	Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 304-383.	1.5	346
105	Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. Journal of the American College of Cardiology, 2013, 62, 1960-1965.	2.8	59
106	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	2.8	331
107	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	1.8	39
108	Dynamic Analysis of Cardiac Rhythms for Discriminating Atrial Fibrillation From Lethal Ventricular Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 555-561.	4.8	28

#	Article	IF	CITATIONS
109	Low-Risk Lifestyle, Coronary Calcium, Cardiovascular Events, and Mortality: Results From MESA. American Journal of Epidemiology, 2013, 178, 12-21.	3.4	80
110	Abstract 442: Correlates of the Triglyceride/HDL Cholesterol Ratio: The Very Large Database of Lipids (VLDL-4). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0
111	Abstract 362: Characterization of Triglyceride-Rich Remnant Lipoproteins in the Hypertriglyceridemic Fredrickson-Levy Dyslipidemic Phenotypes without Chylomicrons: The Very Large Database of Lipids (VLDL-6). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0
112	Abstract 361: Characterization of Lipoproteins in the Hypertriglyceridemic Fredrickson-Levy Dyslipidemic Phenotypes with Chylomicrons: The Very Large Database of Lipids (VLDL-7). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0
113	Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism. Journal of Clinical Lipidology, 2012, 6, 27-32.	1.5	12
114	Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data. PLoS ONE, 2012, 7, e33692.	2.5	20
115	Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the Meantime, Some Challenges and Recommendations. American Journal of Cardiology, 2012, 110, 307-313.	1.6	39
116	Potential Use of Coronary Artery Calcium Progression to Guide the Management of Patients at Risk for Coronary Artery Disease Events. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 69-80.	0.9	8
117	Coronary Artery Calcium Progression: An Important Clinical Measurement?. Journal of the American College of Cardiology, 2010, 56, 1613-1622.	2.8	214